Arcturus Therapeutics (ARCT) Tops Q1 EPS by 6c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($1.00), $0.06 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $38.01 million versus the consensus estimate of $30.91 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Wells Fargo Starts Vivmark Residential (VMRK) at Overweight, 'Setting the mark for growth'
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04